Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Valuation with cash multiples

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Private equity investments in new and emerging drug companies.
Figure 2: Comparison of public and private equity market cash mulitples.
Figure 3: Venture multiples have declined since the 1990s.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Booth, B. Valuation with cash multiples. Nat Rev Drug Discov 4, 533–534 (2005). https://doi.org/10.1038/nrd1779

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1779

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing